Lotiglipron

Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) [1].

Product Specifications

CAS Number

[2401892-75-7]

Product Name Alternative

PF-07081532

UNSPSC

12352005

Target

GLP Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lotiglipron.html

Purity

98.96

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

C[C@@]1(C2=CC=C(C=N2)Cl)OC3=C(C4CCN(CC4)CC(N(C5=C6)C[C@@H]7CCO7)=NC5=CC=C6C(O)=O)C=CC=C3O1

Molecular Formula

C31H31ClN4O5

Molecular Weight

575.05

References & Citations

[1]Buckeridge C, et al. Once-daily oral small molecule GLP-1R agonist PF-07081532 reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity. Hybrid 58th EASD Annual Meeting; Sept 19–23, 2022 (abstr 114) .|[2]Sloop KW, et al., The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024 Dec 18;16 (778) :eadp5765.